penta-refractory multiple myeloma

September 28, 2018

Karyopharm’s Selinexor Demonstrates High Response Rates in Heavily-treated Multiple Myeloma Patients

News

Updated results from a Phase 2b clinical trial continue to support Karyopharm Therapeutics‘ investigative oral therapy selinexor (KPT-330) as a promising approach for heavily-treated multiple myeloma patients who have exhausted all approved ... Read more

May 9, 2018May 10, 2018

Selinexor May Bring Hope to Heavily Treated Myeloma Patients, Trial Results Show

News

A quarter of heavily treated patients with penta-refractory multiple myeloma responded to Karyopharm‘s investigative oral therapy selinexor (KPT-330), according to top-line data from a Phase 2 study. The results bring ... Read more

April 13, 2018April 13, 2018

Selinexor Gains FDA Fast Track Designation for Refractory Multiple Myeloma Patients

News

Selinexor, the lead oral therapy developed by Karyopharm Therapeutics, received Fast Track designation by the U.S. Food and Drug Administration (FDA), for the treatment of refractory multiple myeloma patients — those ... Read more